Finance

Lists
Why is ALLO down 2,60%?
Dive Deeper
ALLO:NASDAQ
Allogene Therapeutics Inc
1,50 $
-2,60%
(-0,040) 1D
1,49 $
-0,67% (-0,0100)
Pre-market
Closed: 2 հոկ, 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ALLO...
Open
1,57 $
High
1,58 $
Low
1,50 $
Mkt. cap
518,24 մլն
Avg. vol.
5,48 մլն
Volume
29,62 հզր
52-wk high
4,46 $
52-wk low
1,04 $
EPS
-0,67 $
Beta
0,56
Shares outstanding
345,49 մլն
No. of employees
150
Open
1,57 $
High
1,58 $
Low
1,50 $
Mkt. cap
518,24 մլն
Avg. vol.
5,48 մլն
Volume
29,62 հզր
52-wk high
4,46 $
52-wk low
1,04 $
EPS
-0,67 $
Beta
0,56
Shares outstanding
345,49 մլն
No. of employees
150
News stories
From web sources and news partners
About Allogene Therapeutics Inc
CEO-
Employees150
Founded2017
HeadquartersSouth San Francisco, Կալիֆոռնիա, Միացյալ Նահանգներ
Sector-
Analyst ratings
Based on 7 analysts giving stock ratings to ALLO in the past 3 months
Strong buy
Buy
6
Hold
1
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for ALLO in the last 3 months.
Highest
Current 1,50 $
14,00 $ (+833,33%)
Average
10,25 $ (+583,33%)
Lowest
8,00 $ (+433,33%)
Analyst
Recommendation
Action
Price target
Projected
Date
John Newman
Canaccord Genuity
Buy
Maintained
14,00 $
+833,3%
09/30/2026
Brian Cheng
J.P. Morgan
Hold
Maintained
-
-
08/17/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
08/12/2026
Unknown Analyst
UBS
Buy
Reiterated
8,00 $
+433,3%
08/13/2026
Luca Issi
RBC Capital
Buy
Reiterated
9,00 $
+500%
08/12/2026
Biren Amin
Piper Sandler
Buy
Maintained
10,00 $
+566,7%
08/13/2026
Sami Corwin
William Blair
Buy
Maintained
-
-
08/13/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
7,00 $
+366,7%
05/14/2026
Roger Song
Jefferies
Buy
Maintained
10,00 $
+566,7%
04/15/2026
Jack Allen
Robert W. Baird
Buy
Maintained
9,00 $
+500%
04/14/2026
William Pickering
Bernstein
Hold
Maintained
3,85 $
+156,7%
04/14/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
11,00 $
+633,3%
04/16/2026
Reni Benjamin
Citizens JMP
Buy
Maintained
8,00 $
+433,3%
04/14/2026
Samantha Semenkow
Citi
Buy
Reiterated
4,00 $
+166,7%
04/09/2026
Asthika Goonewardene
Truist Financial
Buy
Maintained
10,00 $
+566,7%
03/13/2026
Last report
12 օգս, 2026 թ.
Fiscal period
Q2 2026
EPS / Est. (USD)
-0,13 $ / -0,15 $
+12,16%beat
Revenue / Est. (USD)
4,64 մլն / 2,22 հզր
+208 909,01%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
-
-
-
4,64 մլն
Cost of goods sold
31,16 մլն
28,63 մլն
32,00 մլն
30,72 մլն
Cost of revenue
31,16 մլն
28,63 մլն
32,00 մլն
30,72 մլն
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
13,74 մլն
13,77 մլն
14,09 մլն
20,84 մլն
Operating expense
13,74 մլն
13,77 մլն
14,09 մլն
20,84 մլն
Total operating expenses
44,90 մլն
42,40 մլն
46,09 մլն
51,56 մլն
Operating income
-44,90 մլն
-42,40 մլն
-46,09 մլն
-46,92 մլն
Other non operating income
-81,00 հզր
247,00 հզր
212,00 հզր
-61,00 հզր
EBT including unusual items
-41,40 մլն
-38,81 մլն
-42,61 մլն
-42,68 մլն
EBT excluding unusual items
-41,40 մլն
-38,81 մլն
-42,61 մլն
-42,68 մլն
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-41,40 մլն
-38,81 մլն
-42,61 մլն
-42,68 մլն
Net profit margin
-
-
-
-919,76%
Earnings per share
-0,19
-0,17
-0,18
-0,13
Interest and investment income
3,93 մլն
3,66 մլն
3,57 մլն
4,65 մլն
Interest expense
-344,00 հզր
-313,00 հզր
-300,00 հզր
-343,00 հզր
Net interest expenses
3,58 մլն
3,35 մլն
3,27 մլն
4,30 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
-41,80 մլն
-39,35 մլն
-43,22 մլն
-44,28 մլն
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google Apps